[go: up one dir, main page]

PE20071309A1 - Anticuerpos para la modulacion de formacion de huesos - Google Patents

Anticuerpos para la modulacion de formacion de huesos

Info

Publication number
PE20071309A1
PE20071309A1 PE2007000174A PE2007000174A PE20071309A1 PE 20071309 A1 PE20071309 A1 PE 20071309A1 PE 2007000174 A PE2007000174 A PE 2007000174A PE 2007000174 A PE2007000174 A PE 2007000174A PE 20071309 A1 PE20071309 A1 PE 20071309A1
Authority
PE
Peru
Prior art keywords
bone formation
antibodies
referred
antibody
ror2
Prior art date
Application number
PE2007000174A
Other languages
English (en)
Inventor
Julia Billiard
Yan Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20071309A1 publication Critical patent/PE20071309A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

REFERIDA A UN ANTICUERPO MONOCLONAL HUMANO O HUMANIZADO O UN FRAGMENTO DE ANTICUERPO DIRIGIDO A LA PROTEINA Ror2, DONDE EL ANTICUERPO ES DEL ISOTIPO IgG. TAMBIEN ESTA REFERIDA A UNA COMPOSICION. DICHOS ANTICUERPOS MODULAN LA ACTIVIDAD DE Ror, PARTICULARMENTE Ror2 Y/O 14-3-3BETA PRODUCIENDO UN EFECTO SOBRE LA FORMACION O RESORCION OSEA Y SON UTILES EN EL TRTATAMIENTO DE TRASTORNOS OSEOS TALES COMO OSTEOPOROSIS Y FRACTURAS
PE2007000174A 2006-02-17 2007-02-15 Anticuerpos para la modulacion de formacion de huesos PE20071309A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77453406P 2006-02-17 2006-02-17
US84423906P 2006-09-13 2006-09-13

Publications (1)

Publication Number Publication Date
PE20071309A1 true PE20071309A1 (es) 2008-02-13

Family

ID=38437973

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000174A PE20071309A1 (es) 2006-02-17 2007-02-15 Anticuerpos para la modulacion de formacion de huesos

Country Status (19)

Country Link
US (1) US20090047287A1 (es)
EP (1) EP1984395A2 (es)
JP (1) JP2009527485A (es)
KR (1) KR20080095269A (es)
AR (1) AR060104A1 (es)
AU (1) AU2007217779A1 (es)
BR (1) BRPI0707864A2 (es)
CA (1) CA2638803A1 (es)
CR (1) CR10212A (es)
EC (1) ECSP088682A (es)
IL (1) IL193271A0 (es)
MX (1) MX2008010511A (es)
NO (1) NO20083497L (es)
PA (1) PA8715601A1 (es)
PE (1) PE20071309A1 (es)
RU (1) RU2008131052A (es)
SV (1) SV2009002997A (es)
TW (1) TW200800266A (es)
WO (1) WO2007098198A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079246A1 (en) * 2010-05-05 2013-03-28 Addex Pharma Sa Methods and Tools for Screening Agents Exhibiting an Activity on Receptors of the Tumor Necrosis Factor Receptor Superfamily
WO2013070033A1 (ko) * 2011-11-09 2013-05-16 주식회사 아이엠헬스케어 골다공증 및 골회전율 진단 스트립
KR101354826B1 (ko) * 2011-12-08 2014-01-27 아주대학교산학협력단 중간엽줄기세포 렙틴분비능을 이용한 골다공증 예방 또는 치료용 물질 스크리닝 방법
WO2013103637A1 (en) * 2012-01-03 2013-07-11 The Board Of Trustees Of The Leland Stanford Junior University Analysis and targeting of ror2 in cancer
JP6463029B2 (ja) * 2013-08-02 2019-01-30 有未 伊谷 ヒト間葉系幹細胞を特異的に認識するモノクローナル抗体並びにこれを用いたヒト間葉系幹細胞の分離及び／または品質評価を行う方法
ES2927112T3 (es) 2014-08-01 2022-11-02 Purec Co Ltd Método para evaluar la calidad de células madre mesenquimatosas humanas y un anticuerpo monoclonal para su uso en dicho método
JP7057557B2 (ja) * 2015-07-31 2022-04-20 国立大学法人大阪大学 上皮疾患に対する治療及び／又は予防有効性を評価する方法、上皮疾患治療剤のスクリーニング方法、及び上皮疾患治療剤
PL3455261T3 (pl) * 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
GB201718985D0 (en) 2017-11-16 2018-01-03 Univ London Queen Mary Treatment
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization
CN115786252B (zh) * 2023-02-07 2023-05-05 赛德特生物制药有限公司 人脐带间充质干细胞成骨诱导分化培养基及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
AU2001238571A1 (en) * 2000-03-14 2001-09-24 Regeneron Pharmaceuticals, Inc. Methods of stimulating cartilage formation
WO2004073731A1 (en) * 2003-02-19 2004-09-02 Aziz Ghahary 14-3-3 protein for prevention and treatment of fibroproliferative disorders
WO2004094641A2 (en) * 2003-04-16 2004-11-04 Wyeth A novel method of modulating bone-realted activity

Also Published As

Publication number Publication date
IL193271A0 (en) 2011-08-01
KR20080095269A (ko) 2008-10-28
RU2008131052A (ru) 2010-03-27
EP1984395A2 (en) 2008-10-29
TW200800266A (en) 2008-01-01
NO20083497L (no) 2008-10-31
CA2638803A1 (en) 2007-08-30
BRPI0707864A2 (pt) 2011-05-10
AU2007217779A1 (en) 2007-08-30
CR10212A (es) 2008-10-03
PA8715601A1 (es) 2008-11-19
SV2009002997A (es) 2009-04-17
ECSP088682A (es) 2008-09-29
WO2007098198A2 (en) 2007-08-30
US20090047287A1 (en) 2009-02-19
JP2009527485A (ja) 2009-07-30
WO2007098198A3 (en) 2008-03-13
AR060104A1 (es) 2008-05-28
MX2008010511A (es) 2008-11-18

Similar Documents

Publication Publication Date Title
PE20071309A1 (es) Anticuerpos para la modulacion de formacion de huesos
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
ATE557042T1 (de) Anti-myostatin-antikörper
UA109658C2 (xx) Антитіло проти cgrp
UA92504C2 (en) Anti-myostatin monoclonal antibody
UA94899C2 (ru) Фиксированное дозирование антител к her
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
EA201000006A1 (ru) Способы и композиции для лечения аллергических заболеваний
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
UA106890C2 (uk) Гуманізоване антитіло до cdcp1
SG10201804945WA (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
NI201200171A (es) Anticuerpos hacia gdf8 humano
AR072985A1 (es) Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union
PE20081179A1 (es) Formulaciones estables de anticuerpos egfr
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
CO6270370A2 (es) Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8
LT2013015A (lt) Farmacinės kompozicijos
MX2015016978A (es) Proteinas de union a antigeno neutralizantes de citomegalovirus.
CO6290643A2 (es) Derivados ciclopropilamina
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Legal Events

Date Code Title Description
FC Refusal